Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results
Sibylle Loibl, Nicholas C Turner, Jungsil Ro, Massimo Cristofanilli, Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, Sherene Loi, Fabrice Andre, Nadia Harbeck, Sunil Verma, Elizabeth Folkerd, Kathy Puyana Theall, Justin Hoffman, Ke Zhang, Cynthia Huang Bartlett, Mitchell Dowsett
The Oncologist | WILEY | Published : 2017
We are grateful to the patients, the investigators, and the study personnel who participated in the PALOMA-3 trial. The authors would also like to acknowledge the efforts of Maria Koehler, who led the study design and collaborated with investigators performing the biochemical analyses. The FSH, LH, and E2 data in the manuscript were generated by the Centre Royal Marsden Hospital. Fulvestrant was provided by AstraZeneca. This study has been presented in part as a poster discussion at the ASCO Annual Meeting, June 3-7, 2016, Chicago, IL, USA. Editorial support was provided by Susan Reinwald, Ph.D., of Complete Healthcare Communications, LLC, and was funded by Pfizer. This study was sponsored by Pfizer. Final approval of the manuscript rested solely with the authors.